SUBSCRIBE
SUBSCRIBE
News   Business   Deals

ImaRx Therapeutics Acquires Abbokinase

May 8, 2006 | 
1 min read
TUCSON, Ariz.--(BUSINESS WIRE)--May 8, 2006--ImaRx Therapeutics, Inc., a biopharmaceutical company developing innovative therapies for vascular diseases including stroke, today announced the Company has acquired the thrombolytic drug Abbokinase®.
Mergers & acquisitions Arizona
MORE ON THIS TOPIC
3D Paper Cut Pair of Lung dotted with yellow tumor bacteria infection spread across on a blue background with no text. Yellow dots as virus infection in the lungs. Vector Illustration.
Business
Gossamer regains rights to lung disease asset from Chiesi after Phase 3 fail
July 27, 2026
 · 
3 min read
 · 
Gabrielle Masson
Big fish eats small, takeover of the company. Art collage.
Mergers & acquisitions
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
July 27, 2026
 · 
2 min read
 · 
Tristan Manalac
Psychedelic drug or psychedelics hallucinogenic drugs and hallucinogens representing states of consciousness and psychology or psychological hallucinating by taking mind altering substances in a 3D illustration style.
Psychedelics
Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
July 24, 2026
 · 
3 min read
 · 
Gabrielle Masson
Illustration showing big red ball swinging into row of dominoes
Job Trends
Biopharma layoffs must double in H2 for 2026 to match 2025 cuts
July 23, 2026
 · 
4 min read
 · 
Angela Gabriel